Question 1

What is Roluperidone?

Accepted Answer

Roluperidone is a Other.

Question 2

How often does Roluperidone appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Roluperidone first tracked by Ergen?

Accepted Answer

First tracked on Jun 01, 2026.

Question 4

When was Roluperidone last mentioned in news?

Accepted Answer

Last active on Jun 01, 2026.

Question 5

What is Roluperidone's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Roluperidone in global news coverage?

Accepted Answer

Attention score of 3, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Roluperidone?

Accepted Answer

Minerva Neurosciences forms SAB for Roluperidone (Jun 01, 2026, 6 articles).

Question 8

How did the "Minerva Neurosciences forms SAB for Roluperidone" event impact Roluperidone?

Accepted Answer

Roluperidone is an investigational drug being evaluated in a Phase 3 clinical trial for negative symptoms of schizophrenia, and its development will be guided by the newly formed Scientific Advisory Board of Minerva Neurosciences.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.